Defining the optimal schedule of drug administration: Art or Science?

Journal of Clinical Oncology

Volumn 26, Issue 11, 2008, Pages 1781-1782

  Twelves, Chris J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BODY SURFACE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; EDITORIAL; HUMAN; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; ANIMAL; BIOLOGICAL MODEL; CLINICAL TRIAL; DISEASE MODEL; DRUG ADMINISTRATION; METHODOLOGY; NOTE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; MODELS, BIOLOGICAL; RESEARCH DESIGN;

EID: 42949125979     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.7769     Document Type: Editorial

References (16)

1. Traina TA, Theodoulou M, Feigin K, et al: Phase I study of a novel capecitabine schedule based upon the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 26:1797-1802, 2008
2. de Gramont A, Bosset JF, Milan C, et al: Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
3. Verril MW, Lee J, Cameron D, et al: Anglo-Celtic IV: First results of a UK National Cancer Res Network pharmacogenetic trial of weekly versus 3 weekly paclitaxel in locally advanced or metastatic breast cancer (MBC). J Clin Oncol 25:33S, 2007 (suppl; abstr LBA1005)
4. Martin DS, Balis ME, Fisher B, et al: Role of murine tumour models in cancer treatment research. Cancer Res 46:2189-2192, 1988
5. Steel, GG: Growth and survival of tumour stem cells in growth kinetics of tumours, in GG (ed): Growth Kinetics of Tumours. Oxford, United Kingdom, Clarendon Press, 1977, pp 217-262
6. Gianni L, Vigani L, Surbone A, et al: Pharmacology and clinical toxicity of 4′-iodo-4′deoxydoxorubicin: An example of successful application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst 82:469-477, 1990
7. Furman WL, Stewart CF, Poquette CA, et al: Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815-1824, 1999
8. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169, 1986
9. Norton L: Conceptual and practical implications of breast tissue geometry: Toward a more effective, less toxic therapy. Oncologist 10:370-381, 2005
10. Norton L, Dugan U, Young D, et al: Optimising chemotherapeutic dose-schedule (CDS) by Norton-Simon modelling: Capecitabine (Xeloda). Presented at the 96th Annual Meeting of American Association for Cancer Research, Anaheim, CA, April 16-20, 2005 (abstr 5007)
11. Traina TA, Theodoulou M, Higgins B, et al: In vivo activity of a novel regimen of capecitabine (C) in a breast cancer xenograft model. The 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006 (abstr 6071)
12. Budman DR, Meropol NJ, Reigner B, et al: Preliminary studies of a novel oral fluropyrimidine carbamate: Capecitabine. J Clin Oncol 16:1795-1802, 1998
13. Mackean M, Planting A, Twelves C, et al: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16:2977-2985, 1998
14. Cassidy J, Dirix L, Bissett D, et al: A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 4:2755-2761, 1998
15. Van Cutsem E, Findlay M, Osterwalder B, et al: Capecitabine, an oral fluropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomised phase II study. J Clin Oncol 18:1337-1345, 2000
16. Haller JG, Cassidy J, Clarke S, et al: Potential regional differences for the tolerability profiles of fluouropyrimidines. J Clin Oncol doi:10.1200/JCO.2007.15.2090